AUTHOR=Ma Lin , Xiao Junjuan , Guan Yaping , Wu Dongfang , Gu Tiantian , Wang Jun 

TITLE=SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.860060

DOI=10.3389/fonc.2022.860060

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Rearrangements of Anaplastic lymphoma kinase (<italic>ALK</italic>) have been discovered as a novel driver mutation in patients with non–small-cell lung cancer (NSCLC). Patients’ responses to ALK tyrosine kinase inhibitors (TKIs) may vary depending on the variations of <italic>ALK</italic> rearrangements they have. It is imperative for clinicians to identify druggable <italic>ALK</italic> fusions in routine practice.</p></sec><sec><title>Case Presentation</title><p>In this study, we discovered a rare <italic>ALK</italic> rearrangement type (<italic>SDK1–ALK</italic>) in a Chinese lung adenocarcinoma patient who responded well to ALK inhibitor SAF-189s. The positive expression of ALK in lung biopsy tissue was verified by IHC analysis. A new <italic>SDK1-ALK</italic> fusion was discovered using NGS. The patient was treated with SAF-189s (160 mg per day) as a first-line therapy and went into continuous remission, with a 12 months progression-free survival at the last follow-up.</p></sec><sec><title>Conclusion</title><p>This is the first case of <italic>SDK1-ALK</italic> fusion with an excellent response to an ALK inhibitor, which will provide better understanding of ALK-TKI applications for NSCLC patients with <italic>ALK</italic> fusion in the future.</p></sec>